Category - Developments

Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...

September 28, 2023

Developments

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...

September 25, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that rencofilstat demonstrated anti-cancer activity across 86% of cancer types in a high-throughput screen on 850 cancer cell lines. At the Broad Institute of MIT and...

September 21, 2023

Developments

Hepion discovers novel rencofilstat action in liver cancer

Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...

September 20, 2023

Developments

Anixa forms cancer business advisory board

Anixa Biosciences (NASDAQ:ANIX) formed a cancer business advisory board (CBAB) with a roster of renowned cancer advocates, executives and physicians to guide the company’s clinical and business development...

September 19, 2023

Developments

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Closely-held Mati Therapeutics completed a dedicated manufacturing facility for products formulated using the company’s Evolute sustained ocular drug delivery platform. Mati expects that the 10,000-square-foot facility...

September 15, 2023

Developments

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...

September 14, 2023

Developments

OKYO completes enrollment in Phase 2 dry eye clinical trial

OKYO Pharma (NASDAQ:OKYO) completed full enrollment of patients in the randomized portion of the Phase 2 clinical trial of topical ocular, OK-101, to treat dry eye disease (DED). A total of 240 patients were enrolled in...

September 8, 2023

Developments

Rani posts successful drug delivery of high-capacity pill

Rani Therapeutics Holdings (NASDAQ:RANI) reported three new positive preclinical studies that support development of a high-capacity oral biologics device, known as the RaniPill HC, a version of the RaniPill capsule...

September 8, 2023

Developments

Opus Genetics doses first patient with gene therapy in LCAS

Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer...

September 7, 2023

Category - Developments

Subscribe